Navidea Biopharmaceuticals Announces $50 Million Credit

New Post Public Reply Private Reply Replies (0) Message Board

Aug 30, 2012 at 3:28 AM

Navidea Biopharmaceuticals Announces $50 Million Credit Facility with Platinum-Montaur Life Sciences

-Transaction provides flexible financial resources to fund short- and long-term development and growth plans-

DUBLIN, Ohio--(BUSINESS WIRE)--Jul. 26, 2012-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Platinum-Montaur Life Sciences, LLC (Montaur) will provide Navidea a credit facility of up to $50 million. This transaction provides the Company with significant, yet flexible, financial resources to fund its development and growth plans. No draws are currently planned in connection with entering into this facility.

Under the terms of the transaction, Montaur has committed to extend up to $15 million in debt, which is available immediately, to the Company at a prime-based interest rate currently at approximately 10 percent per annum. Montaur has committed an additional $20 million upon approval of Lymphoseek on consistent terms, with yet an additional $15 million potentially available on terms to be negotiated. No conversion features or warrants are associated with the facility.

Navidea is currently awaiting a response from the FDA on a New Drug Application that was submitted for Lymphoseek^® , its novel radiopharmaceutical imaging agent intended for use by surgeons in lymphatic mapping procedures associated with solid tumor cancers. Additionally, the Company’s pipeline includes the ongoing development of a number of diagnostic agents: AZD4694, a beta amyloid imaging agent for Alzheimer’s Disease; and RIGScan, a radio-labeled antibody diagnostic being studied in colorectal cancer.

Michael Goldberg, M.D., Principal, Montaur Capital Partners, LLC and Portfolio Manager of Montaur, said, “Navidea has been, and continues to represent, an excellent investment for Montaur. Our commitment to extend Navidea a non-dilutive credit facility is yet another sign of our confidence in Navidea, its expanding product pipeline and its management. We believe this transaction will support Navidea’s business and growth plans well through the launch period for Lymphoseek, by providing readily-available capital to support their business and pursue other desirable products and license opportunities that fit the Company’s aggressive strategy of pipeline development.”

Mark J. Pykett, V.M.D., Ph.D., Navidea’s President and CEO said, “We are energized by Montaur’s significant financial commitment and confidence in Navidea’s future. This transaction will provide us considerable flexibility to continue funding our growth as needed. Our financial partnership with Montaur has afforded us access to potential resources to confidently implement our plans to deepen our portfolio and advance our business as a leader in precision diagnostics.”

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek^® , AZD4694 and RIGScan^TM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com .

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Source: Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc.
Sr. VP & CFO
Brent Larson, 614-822-2330

Navidea Biopharmaceuticals Inc. (NAVB) Stock Research Links

NAVB Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LaserPecker Debuts U1: Innovations in UV Laser Engraving

An Eye on the Future with LaserPecker's U1 This ain't your typical innovation announcement. LaserPecker is shifting the sands with their latest release, the U1, at IFA 2026 in Berlin. For anyone sick of struggling with transparent materials like glass and crystal, this thing promises to be a game-changer, boasting cutting-edge technology in UV laser engraving. While...

TCL CSOT Dazzles IFA 2026 with Future Display Tech

Breaking Ground in Display Technology Picture this: the bustling halls of IFA 2026 in Berlin, teeming with tech enthusiasts and industry leaders. Today marks the start of the grand event where TCL CSOT steps into the spotlight, unveiling a stunning array of next-gen display technologies under the APEX brand. This isn't just another tech show-and-tell; it's TCL’s bold...

Clinical Trials Services Market Set for Big Growth

Eyeing a Market Surge in Clinical Trials Numbers don't lie, and they're painting a promising picture for the clinical trials services market with a solid 8% growth forecasted annually till 2031. From a modest $66.20 billion in 2026, we're looking at ballooning to a hefty $97.41 billion by 2031. What’s cooking? Let me dish it out for you. Key Drivers and Dynamics North...

AARP New York Promotes Affordable 'Staycation' Experiences

Exploring New York Without Breaking the Bank Tough times call for creative solutions, and AARP New York is on the ball. With travel costs soaring and many older New Yorkers scrimping to make ends meet, the 'Staycation' campaign steps in with an offer too good to pass up: uncovering the gems of New York right under our noses without shelling out hefty sums. The plan? Turn...

AI Data Retention: FastGPT’s Detailed Deletion Protocols

In the world of AI-driven applications, data retention has become a hot potato, especially when we're talking about sensitive information like conversation records and audit logs. FastGPT, an open-source AI platform, has decided to tell it like it is by detailing exactly how these data pieces are retained and ultimately booted out. All this info was scattered to the winds...

Ramaco Resources Faces Stock Shake-Up Amid Distribution

Stock Shake-Up In The Coal Industry Something's brewing in the coal mines of West Virginia, and it isn't just the usual dust settling. Ramaco Resources, Inc. (NASDAQ: METC), the metallurgical coal titan, is feeling the heat from some unexpected stock market turbulence, and it's got everyone in the investment trenches scratching their heads. The Yorktown Energy Partners'...

Art and Science Blend in Dr. De La Cruz's Approach

Redefining Aesthetic Surgery: An Artistic Approach The world of plastic surgery is often seen through the lens of beauty and symmetry, but for Dr. Emmanuel De La Cruz, it's like staring into a whole different universe. This Houston-based plastic surgeon isn't just removing fat—he's reshaping the human canvas with the eye of a sculptor. Beyond the Standard Cut and Snip...

TECNO POVA 8 Pro 5G: Blending Speed with Style

TECNO's Newest Launch: A Marriage of Luxurious Design and Performance This ain't just any phone—they've hitched a race car to your pocket. The TECNO POVA 8 Pro 5G Tonino Lamborghini Limited Edition makes a splash, promising to redefine what folks expect from a luxury-tier device, thanks to its endorsed partnership with the iconic Italian brand. But what's all this mean...

Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

CreditRefresh's AI Tackles 1,000+ Disputes Launch Month

AI-Powered Revolution in Credit Disputes Alright, here we are staring down the latest twist in the credit game. CreditRefresh, an AI-driven platform out of Dover, Delaware, has managed to kickstart its journey by challenging over 1,000 credit report errors in just its first month on the market. That's quite a sprint straight from the gate, don't you think? But hey, this...